Form 4: Bausch Health Director Brett Icahn Acquires Shares in Lieu of Cash Compensation

Brett Icahn, a director at Bausch Health Companies Inc., acquired 4,752 common shares in lieu of cash compensation for board service.

Summary

• On June 28, 2024, Brett Icahn, a director of Bausch Health Companies Inc., acquired 4,752 common shares of the company.
• The shares were received in lieu of cash compensation for his service on the Issuer's Board of Directors for the quarter ending June 30, 2024.
• The price of the shares was $6.97.
• Following the transaction, Icahn directly owns 148,612 common shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transaction is a routine compensation matter. The director taking shares instead of cash is a mildly positive signal.

Positives

• A director taking compensation in shares can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's prospects. This transaction reflects a director's compensation strategy.

Comparison to Industry Standards

• Director compensation packages vary across the pharmaceutical industry.
• Some companies offer a mix of cash and equity, while others rely more heavily on one form of compensation.
• Comparing Bausch Health's director compensation structure to peers like Valeant (historical), Allergan, or Teva could provide a benchmark.

Related Party Transactions

• The acquisition of shares by Brett Icahn in lieu of cash compensation is a related party transaction, as he is a director of the company.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders.
• It may signal director confidence to shareholders.

Key Dates